HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100CompaniesDeal TrackerResearch
Biotech

Horizon Therapeutics plc

1
Articles
Deal Party
Top Role
Feb 27, 2026
First Mention
Feb 27, 2026
Last Mention
1.21
Relevance Score

Coverage Timeline

February 2026
Amgen’s $27.8B Horizon Buy: Betting Big on Rare Diseases, Revenue Multiples, and Pipeline Synergies Deals Deal Party
Feb 27, 2026
In Horizon, Amgen is buying two rare disease engines that don’t just deliver growth, but also sport real insulation from generic erosion and PBM discounting.
Related Companies
Celgene Corporation
1 shared
BioMarin Pharmaceutical Inc.
1 shared
Amgen Inc.
1 shared
AstraZeneca PLC
1 shared